Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.82 |
| ▸ | KDR | P35968 | 4/20 | 0.82 |
| ▸ | BRAF | P15056 | 3/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.73 |
| ▸ | SRC | P12931 | 4/20 | 0.73 |
| ▸ | KIT | P10721 | 3/20 | 0.73 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.73 |
| ▸ | CIT | O14578 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 2/20 | 0.73 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.73 |
| ▸ | STK17B | O94768 | 2/20 | 0.73 |
| ▸ | STK10 | O94804 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | LYN | P07948 | 2/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | MET | P08581 | 2/20 | 0.73 |
| ▸ | HCK | P08631 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15565027 | 0.99 | EGFR (0.81) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL7766288 | 0.93 | EGFR (0.73) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL12694361 | 0.91 | EGFR (1.00) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL29577833 | 0.88 | EGFR (0.92) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL28713534 | 0.88 | EGFR (0.92) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL27727371 | 0.87 | EGFR (0.65) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL31491114 | 0.86 | EGFR (0.87) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL7864729 | 0.86 | KDR (0.73) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL10102567 | 0.85 | EGFR (0.83) | EGFRKDRBRAFERBB2SRC | |
| SCHEMBL19612073 | 0.85 | EGFR (0.86) | EGFRKDRBRAFERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041835-A1 | PHARMACEUTICAL COMPOSITION | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2024-02-08 | — | — | US | disclosed |
| EP-2882714-B1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| EP-2976328-B2 | PIPERAZINE DERIVATIVES AS FASN INHIBITORS | MERCK PATENT GMBH (DE) | 2019-07-03 | — | — | EP | disclosed |
| EP-2817310-B1 | 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-21 | — | — | EP | disclosed |
| US-9890140-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2018-02-13 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9796779-B2 | Binding proteins specific for insulin-like growth factors and uses thereof | MEDIMMUNE LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| EP-2807161-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2900643-B1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-3010916-B1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| CN-1688579-A | Condensed pyridines and pyrimidines with TIE2 (TEK) activity | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-20050165035-A1 | Quinazoline derivatives | ASTRAZENECA AB | 2005-07-28 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1292594-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040138240-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | EGFR 3/4885KDR 70/4885BRAF 140/4885 |
| US-20040138240-A1 | Quinazoline derivatives | NQO2, WEE1, CMA1 | EGFR 2914/4885KDR 3721/4885BRAF 799/4885 |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | CXCR2, CXCR1, ACKR3 | EGFR 2694/4885KDR 558/4885BRAF 1715/4885 |
| US-20240041835-A1 | PHARMACEUTICAL COMPOSITION | CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7 | EGFR 2220/4885KDR 4784/4885BRAF 2629/4885 |
| US-20050165035-A1 | Quinazoline derivatives | ERBB2, EGFR, ERBB4 | EGFR 2/4885KDR 16/4885BRAF 21/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | EGFR 1547/4885KDR 1659/4885BRAF 137/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | EGFR 405/4885KDR 3/4885BRAF 3227/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | EGFR 1257/4885KDR 2563/4885BRAF 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.